The role of organochlorine pesticides as environmental factors in Alzheimer's disease in human studies: A systematic review and meta-analysis.

J Alzheimers DisJul 7, 2026 (epub)
Clinical ResearchNeurologyGeriatrics

Zeinab Ghaedrahmat, Farnaz Almasi, Javad Shamsi Goushki et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis investigated the association between organochlorine pesticide (OCP) exposure and Alzheimer's disease (AD) risk in humans. The analysis of four studies revealed a significant association, with an odds ratio of 2.19 (95% CI: 1.40-3.42), indicating that OCP exposure may substantially increase AD risk.

Key findings

  • Pooled analysis showed an odds ratio of 2.19 for the association between OCP exposure and AD risk.
  • The meta-analysis included four eligible studies assessing OCP exposure.
  • Significant heterogeneity was observed among studies (I² = 84.58%).
  • Chronic exposure to lipophilic pesticides may contribute to neurodegenerative processes in AD.

Why it matters

Understanding environmental risk factors like OCPs is crucial for developing preventive strategies against Alzheimer's disease, a growing concern in aging populations. This knowledge can inform public health policies and occupational safety regulations.

Source

PubMed · PMID 42411987

Published in J Alzheimers Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.